Literature DB >> 1571898

The clinical significance of nuclear DNA ploidy pattern in 184 patients with pheochromocytoma.

O Nativ1, C S Grant, S G Sheps, J R O'Fallon, G M Farrow, J A van Heerden, M M Lieber.   

Abstract

Flow cytometric nuclear DNA analysis was performed on paraffin-embedded tissue samples taken from 184 patients with pheochromocytoma and paraganglioma treated between 1960 and 1987. The Hedley technique was used for measurement of nuclear DNA content. Thirty-five percent of the tumors were DNA diploid, 33% showed a DNA tetraploid pattern, and 32% had DNA aneuploid pattern. Familial pheochromocytoma and associated endocrine or neoplastic disorders were more common among patients with DNA nondiploid tumors. Eighty-four percent of the tumors that invaded blood vessels and all patients with regional or distant metastases had tumors classified as DNA tetraploid or DNA aneuploid. Of 22 patients who had disease progression, 21 (95%) had tumors with abnormal DNA ploidy pattern (P less than 0.001). All 12 patients who died of cancer-related disease had abnormal DNA ploidy; none of the patients with DNA diploid tumor (n = 64) have died of pheochromocytoma (P less than 0.01). These results suggest that nuclear DNA ploidy pattern is an important and independent prognostic variable for patients with pheochromocytoma and paraganglioma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1571898     DOI: 10.1002/1097-0142(19920601)69:11<2683::aid-cncr2820691110>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Clinical experience over 48 years with pheochromocytoma.

Authors:  R E Goldstein; J A O'Neill; G W Holcomb; W M Morgan; W W Neblett; J A Oates; N Brown; J Nadeau; B Smith; D L Page; N N Abumrad; H W Scott
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

2.  Dna ploidy of pheochromocytoma on cytology specimen by image analysis.

Authors:  Noriko Kimura; Mika Watanabe; Tsuneo Ookuma; Wakako Miura; Takao Noshiro; Yukio Miura; Hiroshi Nagura
Journal:  Endocr Pathol       Date:  1994-09       Impact factor: 3.943

3.  Risk Stratification in Paragangliomas with PASS (Pheochromocytoma of the Adrenal Gland Scaled Score) and Immunohistochemical Markers.

Authors:  Maithili Mandar Kulkarni; Siddhi Gaurish Sinai Khandeparkar; Sanjay D Deshmukh; R R Karekar; Vandana L Gaopande; Avinash R Joshi; Mrunal V Kesari; R R Shelke
Journal:  J Clin Diagn Res       Date:  2016-09-01

4.  Leu-M1 immunoreactivity and phaeochromocytoma.

Authors:  L Masmiquel; M Castro-Forns; I de Torres; A García; M T Vidal; R Simó
Journal:  J Clin Pathol       Date:  1997-02       Impact factor: 3.411

5.  Giant phaeochromocytoma: case report.

Authors:  L Basso; L Lepre; M Melillo; F Fora; P L Mingazzini; A Tocchi
Journal:  Ir J Med Sci       Date:  1996 Jan-Mar       Impact factor: 1.568

6.  Composite Pheochromocytoma-Ganglioneuroma of the Adrenal Gland: An Uncommon Entity with Distinctive Clinicopathologic Features.

Authors:  King-Yin Lam; Chung-Yau Lo
Journal:  Endocr Pathol       Date:  1999       Impact factor: 3.943

7.  Phenylethanolamine N-methyltransferase downregulation is associated with malignant pheochromocytoma/paraganglioma.

Authors:  Seung Eun Lee; Ensel Oh; Boram Lee; Yu Jin Kim; Doo-Yi Oh; Kyungsoo Jung; Jong-Sun Choi; Junghan Kim; Sung Joo Kim; Jung Wook Yang; Jungsuk An; Young Lyun Oh; Yoon La Choi
Journal:  Oncotarget       Date:  2016-04-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.